已收盘 01-30 16:00:00 美东时间
-0.130
-3.86%
UPDATE 2-Novo's Wegovy pill hits 18,410 US prescriptions in encouraging debut week Adds analyst comments in paragraph 6, 10-13, graphic By Sriparna Roy Jan 23 (Reuters) - Novo Nordisk's NOVOb.CO Wegovy pill was prescribed 18,410 times in the U.S. in the first full week after its launch in an encour
01-23 20:47
LifeMD ( ($LFMD) ) just unveiled an announcement. On January 2, 2026, LifeMD, I...
01-06 22:50
Shares of LifeMD (LFMD) and GoodRx (GDRX) traded higher in the premarket on Monday after the companies announced the availability of Novo Nordisk’s (NVO) Wegovy pill as part of their product offerings...
01-05 21:48
LifeMD adds FDA-approved Wegovy® pill to its virtual weight management platform, offering affordable branded treatment options for eligible patients. Priced starting at $149 per month, the oral GLP-1 therapy aims to expand access to convenient, clinically supported care, enhancing LifeMD's collaboration with Novo Nordisk.
01-05 13:05
LifeMD, Inc. 8.875% CUM PFD A (LFMDP) declares $0.5547/share quarterly dividend, in line with previous. Forward yield 10.4% Payable Jan. 15; for shareholders of record Jan. 5; ex-div Jan. 5. See LFMDP...
2025-12-26 22:52
LifeMD, Inc. has announced a cash dividend of $0.5546875 per share to holders of its 8.875% Series A Cumulative Perpetual Preferred Stock. The dividend will be paid on January 15, 2026, to holders of record as of January 5, 2026. The company provides virtual primary care services and pharmacy solutions.
2025-12-26 13:00
奥麦罗制药涨超75%,YARTEMLEA药物获得FDA批准;德纳维制药涨超38%,获法国制药巨头22亿美元收购;Sidus Space涨超33%,获美国导弹防御局合同>>
2025-12-26 18:41
LifeMD, Inc. was named to both the 2025 Deloitte Technology Fast 500 and TIME's inaugural America’s Growth Leaders of 2026 lists, highlighting its revenue growth, financial stability, and leadership in health technology. The company provides virtual primary care, telemedicine, and specialized treatment across 200 conditions, leveraging a state-of-the-art platform, pharmacy solutions, and strategic partnerships to expand access to affordable care....
2025-11-24 13:00
今日重点评级关注:富国银行:维持Annexon"超配"评级,目标价从14美元升至27美元;瑞穗:上调Relmada Therapeutics评级至"跑赢大市",目标价从1美元升至10美元
2025-11-20 10:28
Analysts have been eager to weigh in on the Healthcare sector with new ratings ...
2025-11-19 18:10